repotrectinib
oral, CNS-penetrant TRK(A-C) kinase inhibitor Ph. II candidate for solid tumors (160 mg QD), approved 2023 from literature starting point Molecular Cancer Therapeutics Turning Point Therapeutics, San Diego, CA
Molecules of the Month - October 2021
Molecules of the Month
- BMS986278
- compound 4c
- AS-0141
- aficamten
- CP-628006
- reldesemtiv
- JNJ-A07
- eliapixant
- repotrectinib
- compound 10
- venglustat
- maralixibat
- compound 44
- compound 1